# BHLHE40

## Overview
BHLHE40, also known as DEC1, is a gene that encodes the basic helix-loop-helix family member e40, a transcription factor belonging to the basic helix-loop-helix (bHLH) protein family. This family is characterized by a structural motif that facilitates dimerization and DNA binding, allowing these proteins to regulate gene expression. The BHLHE40 protein primarily functions as a transcriptional repressor, although it can also activate transcription in specific contexts. It plays a crucial role in various biological processes, including immune response regulation, cell cycle progression, and metabolic pathways. BHLHE40 is involved in the modulation of cytokine production in T cells and macrophage proliferation, highlighting its significance in immune system function. Additionally, BHLHE40 has been implicated in several pathological conditions, such as cancer and bone diseases, where its expression levels can influence disease progression and prognosis (Jarjour2019Bhlhe40; Sethuraman2018BHLHE40; Uyeda2021BHLHE40; Murre2019Helix–loop–helix).

## Structure
BHLHE40, also known as DEC1, is a member of the basic helix-loop-helix (bHLH) protein family. This family is characterized by a conserved structural motif consisting of two amphipathic α helices connected by a loop, which facilitates dimerization (Murre2019Helix–loop–helix). BHLHE40 can form homodimers, which are transcriptionally inactive or act as repressors, binding DNA to regulate gene expression (Torres-Machorro2021Homodimeric). The protein binds to E-box (CACGTG)-type DNA sequences, a common feature among bHLH transcription factors (Seuter2013The).

The primary structure of BHLHE40 includes a basic region that interacts with DNA, adjacent to the helix-loop-helix domain responsible for dimerization (Torres-Machorro2021Homodimeric). While specific details on the secondary, tertiary, and quaternary structures of BHLHE40 are not provided, the general architecture of bHLH proteins involves a parallel four-helix bundle stabilized by hydrophobic interactions (Murre2019Helix–loop–helix).

Post-translational modifications such as phosphorylation may regulate the dimerization and transcriptional activity of bHLH proteins, although specific modifications for BHLHE40 are not detailed in the available context (Torres-Machorro2021Homodimeric).

## Function
BHLHE40, a transcription factor, plays a significant role in regulating cytokine production in human CD4+ T cells, particularly influencing the secretion of IFN-γ, IL-4, IL-2, and IL-10. It is highly expressed in type 1 regulatory T (Tr1) cells, where it acts as an IL-10 inhibitor and promotes IFN-γ production, despite the presence of the IL-10 activator cMAF (Uyeda2021BHLHE40). BHLHE40 is crucial for maintaining the proliferative capacity of T cells, likely through its influence on IL-2 secretion, and is involved in modulating the expression of co-inhibitory receptors like LAG3 and CD49b (Uyeda2021BHLHE40).

In macrophages, BHLHE40 is essential for the proliferation of large peritoneal macrophages (LPMs) in response to IL-4 complex treatment, facilitating their progression through the cell cycle. It binds to genomic sites associated with cell cycle-related proteins, indicating its role as a transcriptional regulator in macrophage proliferation and tissue-specific immune responses (Jarjour2019Bhlhe40). BHLHE40's regulatory functions extend to various hematopoietic cell types, where it primarily acts as a transcriptional repressor, although it can also activate transcription in certain contexts (Jarjour2019Bhlhe40).

## Clinical Significance
Alterations in the expression of the BHLHE40 gene have been implicated in several diseases, particularly various forms of cancer. In breast cancer, BHLHE40 is associated with promoting a pro-survival and pro-metastatic phenotype. Its overexpression can lead to increased cell migration and invasion, particularly in triple-negative breast cancer, where it is linked to poor prognosis and chemoresistance (Sethuraman2018BHLHE40). BHLHE40 influences the transcription of heparin-binding epidermal growth factor (HBEGF), which is crucial for cell proliferation and survival, by sequestering histone deacetylases from the HBEGF promoter (Sethuraman2018BHLHE40).

In pancreatic ductal adenocarcinoma (PDAC), high BHLHE40 expression is associated with poor prognosis, shorter survival, and advanced cancer stages. It is involved in promoting tumor cell stemness and immune evasion, contributing to aggressive tumor behavior (Liu2023The). BHLHE40 is also linked to pre-eclampsia, where its upregulation in the placenta is associated with the down-regulation of miR-196a-5p, contributing to the pathogenesis of the condition (Mi2020BHLHE40). In bone diseases such as osteoporosis, BHLHE40 promotes osteoclast differentiation, suggesting its role in bone resorption and potential as a therapeutic target (Zhang2022BHLHE40).

## Interactions
BHLHE40, also known as DEC1 or STRA13, is a transcription factor that engages in various protein-protein and protein-DNA interactions, influencing multiple cellular processes. It interacts with PGC-1α, a transcriptional coactivator, to repress its activity on metabolic gene promoters in myogenic cells. This repression is facilitated by the recruitment of histone deacetylases (HDACs) and involves direct interaction with the N-terminal activation domain of PGC-1α (Chung2015Bhlhe40). BHLHE40 also interacts with the transcription factor SP1, mediating transcriptional suppression of the CLDN1 gene in breast cancer cells. This interaction does not involve direct binding to E-box motifs but requires the BHLH and Orange domains of BHLHE40 (Zheng2018Interaction).

In prostate cancer cells, BHLHE40 interacts with the androgen receptor (AR), forming a protein-protein complex that may regulate downstream targets through genomic regulation. This interaction is observed in both castration-sensitive and castration-resistant prostate cancer cell lines (Heidari2024The). BHLHE40 also binds to the E-box sequence in the STAT1 promoter, repressing targets of unphosphorylated STAT1, and interacts with phosphorylated STAT3 isoforms to activate STAT-dependent cis-elements (Kiss2020Noncircadian). These interactions highlight BHLHE40's role in regulating gene expression and its involvement in various cellular pathways.


## References


[1. (Liu2023The) Chao Liu, Jiang Du, Jianwei Zheng, Ruizhe Zhang, Jialin Zhu, Bofan Xing, Lin Dong, Qianqian Zhou, Xiaofeng Yao, Song Gao, Yu Wang, Yu Ren, and Xuan Zhou. The role of bhlhe40 in clinical features and prognosis value of pdac by comprehensive analysis and in vitro validation. Frontiers in Oncology, June 2023. URL: http://dx.doi.org/10.3389/fonc.2023.1151321, doi:10.3389/fonc.2023.1151321. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2023.1151321)

[2. (Mi2020BHLHE40) Chunmei Mi, Bin Ye, Zhou Gao, Jinzhi Du, Ruizhen Li, and Dong Huang. Bhlhe40 plays a pathological role in pre-eclampsia through upregulating snx16 by transcriptional inhibition of mir-196a-5p. Molecular Human Reproduction, 26(7):532–548, June 2020. URL: http://dx.doi.org/10.1093/molehr/gaaa037, doi:10.1093/molehr/gaaa037. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/molehr/gaaa037)

[3. (Uyeda2021BHLHE40) Molly Javier Uyeda, Robert A. Freeborn, Brandon Cieniewicz, Rosa Romano, Ping (Pauline) Chen, Jeffrey Mao-Hwa Liu, Benjamin Thomas, Esmond Lee, Alma-Martina Cepika, Rosa Bacchetta, and Maria Grazia Roncarolo. Bhlhe40 regulates il-10 and ifn-γ production in t cells but does not interfere with human type 1 regulatory t cell differentiation. Frontiers in Immunology, July 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.683680, doi:10.3389/fimmu.2021.683680. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.683680)

[4. (Zheng2018Interaction) Qin Zheng, Chen Wang, Liang Wang, Di Zhang, Nan Liu, Xiaocui Ming, Haitao Zhou, Qiere Guli, and Yang Liu. Interaction with sp1, but not binding to the e‐box motifs, is responsible for bhlhe40/dec1‐induced transcriptional suppression of cldn1 and cell invasion in mcf‐7 cells. Molecular Carcinogenesis, 57(9):1116–1129, May 2018. URL: http://dx.doi.org/10.1002/mc.22829, doi:10.1002/mc.22829. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/mc.22829)

[5. (Murre2019Helix–loop–helix) Cornelis Murre. Helix–loop–helix proteins and the advent of cellular diversity: 30 years of discovery. Genes &amp; Development, 33(1–2):6–25, January 2019. URL: http://dx.doi.org/10.1101/gad.320663.118, doi:10.1101/gad.320663.118. This article has 102 citations.](https://doi.org/10.1101/gad.320663.118)

[6. (Jarjour2019Bhlhe40) Nicholas N. Jarjour, Elizabeth A. Schwarzkopf, Tara R. Bradstreet, Irina Shchukina, Chih-Chung Lin, Stanley Ching-Cheng Huang, Chin-Wen Lai, Melissa E. Cook, Reshma Taneja, Thaddeus S. Stappenbeck, Gwendalyn J. Randolph, Maxim N. Artyomov, Joseph F. Urban, and Brian T. Edelson. Bhlhe40 mediates tissue-specific control of macrophage proliferation in homeostasis and type 2 immunity. Nature Immunology, 20(6):687–700, May 2019. URL: http://dx.doi.org/10.1038/s41590-019-0382-5, doi:10.1038/s41590-019-0382-5. This article has 66 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41590-019-0382-5)

[7. (Heidari2024The) Mehdi Heidari Horestani, Golnaz Atri Roozbahani, and Aria Baniahmad. The clock gene bhlhe40 and atypical ccng2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer. Journal of Experimental &amp; Clinical Cancer Research, June 2024. URL: http://dx.doi.org/10.1186/s13046-024-03097-6, doi:10.1186/s13046-024-03097-6. This article has 0 citations.](https://doi.org/10.1186/s13046-024-03097-6)

[8. (Seuter2013The) Sabine Seuter, Petri Pehkonen, Sami Heikkinen, and Carsten Carlberg. The gene for the transcription factor bhlhe40/dec1/stra13 is a dynamically regulated primary target of the vitamin d receptor. The Journal of Steroid Biochemistry and Molecular Biology, 136:62–67, July 2013. URL: http://dx.doi.org/10.1016/j.jsbmb.2012.11.011, doi:10.1016/j.jsbmb.2012.11.011. This article has 18 citations.](https://doi.org/10.1016/j.jsbmb.2012.11.011)

[9. (Kiss2020Noncircadian) Zsofia Kiss, Maria Mudryj, and Paramita M. Ghosh. Non-circadian aspects of bhlhe40 cellular function in cancer. Genes &amp; Cancer, 11(1–2):1–19, March 2020. URL: http://dx.doi.org/10.18632/genesandcancer.201, doi:10.18632/genesandcancer.201. This article has 27 citations.](https://doi.org/10.18632/genesandcancer.201)

[10. (Torres-Machorro2021Homodimeric) Ana Lilia Torres-Machorro. Homodimeric and heterodimeric interactions among vertebrate basic helix–loop–helix transcription factors. International Journal of Molecular Sciences, 22(23):12855, November 2021. URL: http://dx.doi.org/10.3390/ijms222312855, doi:10.3390/ijms222312855. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms222312855)

[11. (Zhang2022BHLHE40) Yufeng Zhang, Min Yang, Sheng Zhang, Zhiqiang Yang, Yufan Zhu, Yi Wang, Zhe Chen, Xuan Lv, Zan Huang, Yuanlong Xie, and Lin Cai. Bhlhe40 promotes osteoclastogenesis and abnormal bone resorption via c-fos/nfatc1. Cell &amp; Bioscience, May 2022. URL: http://dx.doi.org/10.1186/s13578-022-00813-7, doi:10.1186/s13578-022-00813-7. This article has 9 citations.](https://doi.org/10.1186/s13578-022-00813-7)

[12. (Sethuraman2018BHLHE40) Aarti Sethuraman, Martin Brown, Raya Krutilina, Zhao-Hui Wu, Tiffany N. Seagroves, Lawrence M. Pfeffer, and Meiyun Fan. Bhlhe40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating hbegf secretion. Breast Cancer Research, October 2018. URL: http://dx.doi.org/10.1186/s13058-018-1046-3, doi:10.1186/s13058-018-1046-3. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/s13058-018-1046-3)

[13. (Chung2015Bhlhe40) Shih Ying Chung, Chien Han Kao, Francesc Villarroya, Hsin Yu Chang, Hsuan Chia Chang, Sheng Pin Hsiao, Gunn-Guang Liou, and Shen Liang Chen. Bhlhe40 represses pgc-1α activity on metabolic gene promoters in myogenic cells. Molecular and Cellular Biology, 35(14):2518–2529, July 2015. URL: http://dx.doi.org/10.1128/MCB.00387-15, doi:10.1128/mcb.00387-15. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.00387-15)